Skip to main content

Please note that this is a beta version of our website. Should you encounter any bugs, glitches, lack of functionality or other problems on the website, please let us know immediately so we can rectify these accordingly. Your help in this regard is greatly appreciated! You can email us.

Login to North West London Pathology – consumables service

If you need a new account or you have a query about your order, please telephone the pathology call centre on 0203 313 5353.

If you have forgotten your password you can reset this yourself. Please click here if you have forgotten your password.

Results Line and Enquiries

0203 313 5353

Lupus anticoagulant (LA) screen

Category Haematology >> Specialised Coagulation Services
Test background

LA is a group of antibodies found in patients with SLE, as well as other autoimmune disorders and recurrent fetal loss. Although associated with thrombotic events, it may be characterised by a prolonged APTT, due to an in vitro anticoagulant effect (in contrast to the prothrombotic in vivo effect). Screening for lupus anticoagulant is performed as part of the screen for antiphospholipid syndrome and should therefore be performed in conjunction with a cardiolipin antibody test. See Cardiolipin antibodies, Immunology.

Clinicial Indications

Unexplained arterial or venous thrombosis Venous thromboembolism at a young age (including childhood) Recurrent venous thromboembolism Unusual site of thrombosis (eg. mesenteric, renal, portal veins, cerebral venous sinuses) Thrombosis during pregnancy or puerperium Recurrent superficial thrombophlebitis Arterial thrombosis at a young age (abruptio placentae, pre-term delivery) Neonatal purpura fulminars or massive thrombosis in newborn

Sample & container required 3 x 4.5 mL sodium citrate (pale blue top)
Turnaround time 14 days
Notes

Special handling: avoid prolonged stasis during venepuncture. Sample must be received by lab within 2 hours of collection. Please note: samples will be rejected if underfilled, clotted or haemolysed, or if they come from patients receiving anticoagulant therapy. Similarly, sampling is inappropriate within 4 weeks post-childbirth, or during an acute phase inflammatory response.